Since the first human genome was sequenced in 2003, at a cost of $3 billion, Genomics companies have been innovating to provide less expensive, faster, and higher quality solutions. This high-growth industry is currently valued at an estimated $15.5 billion, with further growth predicted to tip 8.6% over the next five years.
Consolidation in the genomics industry is common for technology companies through M&A or partnerships to build complementary solutions. We are also seeing expansion in NIPT (non-invasive prenatal testing). The industry has an expanding base of funding from venture capitalists. Research and new technologies are quickly moving to commercial applications and are raising significant amounts of capital. In 2019, the total investment in genomics was nearly $5 billion with investments in 154 companies.
In our Genomics Industry Report, we explore a sector overview, demand trends, industry transaction activity, insights into select active acquirers, and more.
Objective Capital Partners has decades of experience and our tenacious advocacy for our clients has allowed us to create and maintain relationships with active acquirers and investors in our industries of focus. Whether preparing for sale or strategizing for future exit options, knowing the active acquirers and investors within your industry niche is an important factor in achieving your transaction goals.
If you are interested in learning more about the trends and insights in the Genomics Industry, or if you would like to discuss your own acquisition goals, contact us at (800) 849-7010 or [email protected].
About the Author:
10+ Years of Experience
Objective Capital Partners is a leading investment banking advisory firm whose Principals have collectively engaged in more than 500 successful transactions serving the transaction needs of growth stage and mid-size companies. The executive team has a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to companies with annual revenues up to $250MM. Services include sale transactions, partnering/ licensing, equity and debt capital raises, valuation and comprehensive advisory services. The firm uses a proprietary process to work to achieve maximum company valuation, premium pricing, and high client satisfaction rates post-sale. The firm’s industry expertise is focused on 5 verticals including healthcare, life sciences, business services, technology, and consumer products. Additional information on Objective Capital Partners is available at www.objectiveibv.com.
This article is provided for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. Objective Capital Partners and BA Securities are separate and unaffiliated entities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.